FrancophonIA/ELRC3.0 huggingface dataset:
English: b Includes subjects who had ≥ 50 copies/mL in the week 48 or week 96 window, subjects who discontinued early due to lack or loss of efficacy, subjects who had a viral load ≥ 50 copies/mL at time of change in background regimen, subjects who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral load of ≥ 50 copies/mL.
Slovenian: a Okno v 48. tednu je med 309. in 364. dnevom (vključno z njima), okno v 96. tednu je med 645. in 700. dnevom (vključno b Vključuje osebe, ki so imele v oknu 48. ali 96. tedna ≥ 50 kopij/ml, osebe, ki so predčasno prekinile sodelovanje zaradi pomanjkanja ali izgube učinka, osebe, ki so imele virusno obremenitev ≥ 50 kopij/ml v času spremembe osnovnega režima, osebe, ki so sodelovanje prekinile zaradi razlogov, ki niso bili neželeni učinki, smrt ali pomanjkanje oz. izguba učinka, in so imele v času prekinitve virološko obremenitev ≥ 50 kopij/ml.
English: No interactions were studied using unboosted elvitegravir.
Slovenian: Interakcij z neojačanim elvitegravirjem niso preučili.
English: Vitekta must be administered in combination with a ritonavir-boosted protease inhibitor.
Slovenian: Zdravilo Vitekta je treba dajati v kombinaciji z zaviralcem proteaze, ojačanim z ritonavirjem.
English: It is recommended to separate Vitekta and antacid administration by at least 4 hours.
Slovenian: Priporoča se vsaj 4-urni razmak med dajanjem zdravila Vitekta in antacida.
English: Among subjects with a genotypic sensitivity score > 1, 57% and 56% had HIV-1 RNA < 50 copies/mL at week 48 in the elvitegravir and raltegravir treatment arms, respectively.
Slovenian: Med osebami z rezultatom genotipske občuljivosti > 1 jih je imelo 57 % oz. 56 % HIV-1 RNA < 50 kopij/ml v 48. tednu v kraku z elvitegravirjem oz. kraku z raltegravirjem.
English: Table 6: Virologic success by co-administered protease inhibitor in study GS-US-183-0145 at week 48 and week 96 (snapshot analysis)
Slovenian: Preglednica 6: Virološki uspeh sočasno uporabljenega zaviralca proteaze v študiji GS-US-183-0145 v 48. in 96. tednu (analiza posnetka stanja)
English: For use of the 85 mg tablet, please refer to the Summary of Product Characteristics for Vitekta 85 mg tablets.
Slovenian: Za uporabo 85 mg tablete glejte povzetek glavnih značilnosti zdravila za zdravilo Vitekta 85 mg tablete.
English: In study GS-US-183-0145, the mean increase from baseline in CD4+ cell count at week 96 was in the elvitegravir-treated patients and 198 cells/mm in the raltegravir-treated patients.
Slovenian: V študiji GS-US-183-0145 je bilo povprečno povečanje od začetne vrednosti za število celic CD4+ v 96. tednu 205 celic/mm za bolnike, zdravljene z elvitegravirjem, in 198 celic/mm za bolnike,
English: Following oral administration of a single dose of ritonavir-boosted [
Slovenian: Po peroralnem dajanju enega odmerka z ritonavirjem ojačanega [
English: Lopinavir/Ritonavir has been shown to significantly increase the plasma concentrations of elvitegravir.
Slovenian: Pokazalo se je, da lopinavir/ritonavir močno povečata koncentracije elvitegravirja v plazmi.
English: Patients receiving Vitekta or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Slovenian: Pri bolnikih, ki se zdravijo z zdravilom Vitekta ali s katero koli drugo obliko protiretrovirusne terapije, se lahko še naprej razvijajo oportunistične okužbe in drugi zapleti okužbe z virusom HIV.
English: No dose adjustment is required when Vitekta is co-administered with atorvastatin, fluvastatin, pitavastatin or pravastatin.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z atorvastatinom, fluvastatinom, pitavastatinom ali pravastatinom.
English: A study of the pharmacokinetics of boosted elvitegravir was performed in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B).
Slovenian: Pri osebah z zmerno jetrno okvaro brez okužbe z virusom HIV-1 so izvedli farmakokinetično študijo ojačanega elvitegravirja z zmerno jetrno okvaro (stopnje B po Child-Pughu).
English: Among subjects with a genotypic sensitivity score of ≤ 1, 76% and 69% had HIV-1 RNA < 50 copies/mL at week 48 in the elvitegravir and raltegravir treatment arms, respectively.
Slovenian: Med osebami z rezultatom genotipske občutljivosti ≤ 1 jih je imelo 76 % oz. 69 % HIV-1 RNA < 50 kopij/ml v 48. tednu v kraku z elvitegravirjem oz. kraku z raltegravirjem.
English: In an analysis of HIV-1 isolates from treatment-failure subjects in study GS-US-183-0145 through week 96, the development of one or more primary elvitegravir resistance-associated substitutions was observed in 23 of the 86 subjects with evaluable genotypic data from paired baseline and elvitegravir treatment-failure isolates (23/351 elvitegravir-treated subjects, 6.6%).
Slovenian: V analizi izolatov HIV-1 pri bolnikih, pri katerih je bilo zdravljenje v študiji GS-US-183-0145 do konca 96. tedna neuspešno, so pri 23 od 86 oseb, pri katerih je bilo mogoče oceniti genotipske podatke iz parov izolatov ob začetku in po neuspešnem zdravljenju z elvitegravirjem (23/351 oseb, zdravljenih z elvitegravirjem, 6,6 %), opazili razvoj ene ali več primarnih, z rezistenco povezanih substitucij elvitegravirja.
English: • multivitamins, used to supplement your diet (see also section 3 of this leaflet).
Slovenian: • multivitamine, uporabljajo se kot prehransko dopolnilo (glejte tudi poglavje 3 tega navodila)  Povejte svojemu zdravniku, če kar koli od tega velja za vas.
English: Physicians should refer to current HIV treatment guidelines for the optimal management of HIV infection in patients co-infected with hepatitis B virus (HBV).
Slovenian: Za optimalno zdravljenje okužbe z virusom HIV pri bolnikih, ki so hkrati okuženi z virusom hepatitisa B (HBV), naj zdravniki upoštevajo trenutno veljavne smernice za zdravljenje HIV.
English:  If any of these applies to you, talk to your doctor before taking Vitekta.
Slovenian:  Če kar koli od navedenega velja za vas, se pred jemanjem zdravila Vitekta posvetujte s
English: It is recommended that the international normalised ratio (INR) be monitored upon co-administration of Vitekta.
Slovenian: Pri sočasnem dajanju zdravila Vitekta se priporoča spremljanje mednarodnega normaliziranega razmerja (INR - international normalised ratio).
English: No dose adjustment of Vitekta is required for patients with renal impairment.
Slovenian: Prilagajanje odmerka zdravila Vitekta za bolnike z ledvično okvaro ni potrebno.
English: No dose adjustment of Vitekta is necessary for patients with mild to moderate hepatic impairment.
Slovenian: Prilagajanje odmerka zdravila Vitekta za bolnike z blago do zmerno jetrno okvaro ni potrebno.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg of elvitegravir.
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena filmsko obložena tableta vsebuje 150 mg elvitegravirja.
English: No dose adjustment is required when Vitekta is co-administered with tenofovir disoproxil fumarate or with emtricitabine.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z dizoproksiltenofovirat fumaratom ali emtricitabinom.
English: The Summary of Product Characteristics for the co-administered ritonavir-boosted protease inhibitor
Slovenian: Glejte Povzetek glavnih značilnosti zdravila sočasno danega zaviralca proteaze, ojačanega z
English: §Due to inhibition of CYP3A by ritonavir, maraviroc exposure is significantly increased.
Slovenian: Ker ritonavir zavira CYP3A, je izpostavljenost maraviroku močno povečana.
English: Vitekta film-coated tablets are green, triangle-shaped tablets, debossed on one side with “GSI” and “150” on the other side of the tablet.
Slovenian: Zdravilo Vitekta filmsko obložene tablete so zelene, trikotne tablete, z vtisnjenim znakom “GSI” na eni strani tablete in številko “150” na drugi strani tablete.
English: Each film-coated tablet contains 85 mg elvitegravir.
Slovenian: Ena filmsko obložena tableta vsebuje 85 mg elvitegravirja.
English: Due to inhibition of CYP3A by ritonavir, ketoconazole exposure is increased.
Slovenian: Ker ritonavir zavira CYP3A, je izpostavljenost ketokonazolu povečana.
English: 4.2 Posology and method of administration Therapy should be initiated by a physician experienced in the management of HIV infection.
Slovenian: Terapijo mora začeti zdravnik, ki že ima izkušnje z zdravljenjem okužbe z virusom HIV.
English: Resistance
Slovenian: Absorpcija
English: -21.4% (-73.6% to 30.7%)
Slovenian: -21,4 % (-73,6 % do
English: Refer to the package leaflet for Vitekta 150 mg tablets.
Slovenian: Glejte navodilo za uporabo zdravila Vitekta 150 mg tablete.
English: Accordingly, when used in combination with atazanavir/ritonavir and lopinavir/ritonavir, the dose of Vitekta should be decreased from 150 mg once daily to 85 mg once daily (see sections 4.2 and 4.4).
Slovenian: Ustrezno je treba pri uporabi v kombinaciji z atazanavirjem/ritonavirjem in lopinavirjem/ritonavirjem odmerek zdravila Vitekta zmanjšati s 150 mg enkrat na dan na 85 mg enkrat na dan (glejte poglavji 4.2 in 4.4).
English: Plasma concentrations of elvitegravir are not expected to change upon co-administration of OATP substrates/inhibitors.
Slovenian: Ne pričakuje se, da bi sočasno dajanje elvitegravirja spremenilo koncentracije substratov OATP v plazmi.
English: • cobicistat
Slovenian: • kobicistat
English: Vitekta film-coated tablets are green, pentagon-shaped tablets, debossed on one side with “GSI” and “85” on the other side of the tablet.
Slovenian: Zdravilo Vitekta filmsko obložene tablete so zelene, peterokotne tablete, z vtisnjenim znakom “GSI” na eni strani tablete in številko “85” na drugi strani tablete.
English: No dose adjustment of Vitekta is required in patients with mild (Child-Pugh Class A) or moderate hepatic impairment (Child-Pugh Class B) (see sections 4.2 and 5.2).
Slovenian: Pri bolnikih z blago (stopnja A po Child-Pughu) ali zmerno (stopnja B po Child-Pughu) jetrno okvaro prilagoditev odmerka zdravila Vitekta ni potrebna (glejte poglavji 4.2 in 5.2).
English: Vitekta 85 mg film-coated tablets Elvitegravir
Slovenian: Vitekta 85 mg filmsko obložene tablete elvitegravir
English:  If you get any side effects, talk to your doctor or pharmacist.
Slovenian:  Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali farmacevtom.
English: Vitekta 85 mg film-coated tablets
Slovenian: Vitekta 85 mg filmsko obložene tablete
English: Elvitegravir undergoes oxidative metabolism by CYP3A (major route), and glucuronidation by UGT1A1/3 enzymes (minor route).
Slovenian: Elvitegravir se presnavlja z oksidacijo s CYP3A (glavna pot) in glukuronidacijo z encimi UGT1A1/3
English: No human data on the effect of elvitegravir on fertility are available.
Slovenian: Ni podatkov o učinkih elvitegravirja na sposobnost razmnoževanja pri ljudeh.
English: When used in combination with atazanavir/ritonavir and lopinavir/ritonavir, the dose of Vitekta should be decreased from 150 mg once daily to 85 mg once daily (see section 4.2).
Slovenian: Pri uporabi v kombinaciji z atazanavirjem/ritonavirjem in lopinavirjem/ritonavirjem je treba odmerek zdravila Vitekta zmanjšati s 150 mg enkrat na dan na 85 mg enkrat na dan (glejte poglavje 4.2).
English: Vitekta 150 mg film-coated tablets Elvitegravir
Slovenian: Vitekta 150 mg filmsko obložene tablete elvitegravir
English: Vitekta 150 mg film-coated tablets
Slovenian: Vitekta 150 mg filmsko obložene tablete
English: Do not change the dose unless your doctor tells you to. You must always take Vitekta with one of the following combinations of medicines:
Slovenian: Zdravilo Vitekta morate vedno jemati v eni od kombinaciji z naslednjimi zdravil:
English: Table 1: Recommended dosing regimens Dose of Vitekta
Slovenian: Preglednica 1: Priporočeni režimi odmerjanja Odmerek zdravila Vitekta Odmerek sočasno uporabljenega zaviralca proteaze, ojačanega z ritonavirjem
English: Talk to your doctor before taking Vitekta:
Slovenian: Pred začetkom jemanja zdravila Vitekta se posvetujte z zdravnikom:
English: ↑ Ketoconazole§
Slovenian: Ελλάδα
English: Refer to the package leaflet for Vitekta 85 mg tablets.
Slovenian: Glejte navodilo za uporabo zdravila Vitekta 85 mg tablete.
English: • suicidal thoughts and suicide attempts (in patients who have had depression or mental health
Slovenian: (pojavijo se lahko pri največ 1 od 100 bolnikov, ki se zdravijo) • samomorilne misli in poskusi samomora (pri bolnikih z depresijo ali duševno boleznijo
English: Vitekta is not recommended in this
Slovenian: Uporaba zdravila Vitekta pri tej populaciji ni
English: Each film-coated tablet contains 150 mg elvitegravir.
Slovenian: Ena filmsko obložena tableta vsebuje 150 mg elvitegravirja.
English: Elvitegravir (125 mg once daily) Ritonavir (100 mg twice daily)
Slovenian: dnevno) elvitegravir (125 mg enkrat dnevno) ritonavir (100 mg dvakrat dnevno)
English: When used in combination with atazanavir, the dose of Vitekta should be 85 mg once daily.
Slovenian: Pri uporabi v kombinaciji z atazanavirjem mora biti odmerek zdravila Vitekta 85 mg enkrat dnevno.
English: When used in combination with lopinavir/ritonavir, the dose of Vitekta should be 85 mg once daily.
Slovenian: Pri uporabi v kombinaciji z lopinavirjem/ritonavirjem mora biti odmerek zdravila Vitekta 85 mg enkrat dnevno.
English: When used in combination with fosamprenavir, the dose of Vitekta should be 150 mg once daily.
Slovenian: Pri uporabi v kombinaciji s fosamprenavirjem mora biti odmerek zdravila Vitekta 150 mg enkrat dnevno.
English: Elvitegravir
Slovenian: • ščemenje
English: Look out for signs of inflammation or infection soon after you start taking Vitekta.
Slovenian: Takoj po začetku jemanja zdravila Vitekta bodite pozorni na znake vnetij ali okužb.
English: No dose adjustment is required when Vitekta is co-administered with ketoconazole.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno s ketokonazolom.
English: Excipients
Slovenian: Znaki
English: Do not stop your treatment
Slovenian: Ne prekinite zdravljenja brez posvetovanja z zdravnikom.
English: No dose adjustment is required when Vitekta is co-administered with ritonavir-boosted atazanavir plus telaprevir.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z atazanavirjem, ojačanim z ritonavirjem, in telaprevirjem.
English: Although limited by the small number of female subjects in study GS-US-183-0145, subgroup analysis by gender showed that the rates of virologic success in female subjects at weeks 48 and 96 (HIV-1 RNA < 50 copies/mL) were numerically lower in the elvitegravir treatment arm than in the raltegravir treatment arm. Virologic success rates at week 48 for elvitegravir and raltegravir were 47.5% (28/59) and 62.7% (42/67) (difference: -12.3% [95% CI: -30.1% to 5.5%]), respectively, for female subjects, and 62.3% (182/292) and 56.3% (160/284) (difference: 5.3% [95% CI: -2.5% to 13.2%]), respectively, for male subjects.
Slovenian: Stopnje virološkega uspeha v 48. tednu so bile pri ženskah 47,5 % (28/59) za elvitegravir in 62,7 % (42/67) za raltegravir (razlika: -12,3 % [95-% IZ: -30,1 % do 5,5 %]), ter pri moških 62,3 % (182/292) za elvitegravir in 56,3 % (160/284) za raltegravir (razlika: 5,3 % [95-% IZ: -2,5 % do 13,2 %]).
English: There are no data available to make dosing recommendations for co-administration with other doses of lopinavir/ritonavir (see section 4.2).
Slovenian: Podatkov za izdelavo priporočil o odmerjanju pri sočasnem dajanju z drugimi odmerki lopinavirja/ritonavirja ni (glejte poglavje 4.2).
English: Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AX11.
Slovenian: Farmakoterapevtska skupina: Sistemski virostatiki; druga zdravila za sistemsko zdravljenje virusnih
English: There are no data available to make dosing recommendations for co-administration with other doses of atazanavir (see section 4.2).
Slovenian: Podatkov za izdelavo priporočil o odmerjanju pri sočasnem dajanju z drugimi odmerki atazanavirja ni (glejte poglavje 4.2).
English: Elvitegravir (150 mg once daily) Ritonavir (100 mg once daily)
Slovenian: dnevno) elvitegravir (150 mg enkrat dnevno) ritonavir (100 mg enkrat dnevno)
English: No dose adjustment is required when Vitekta is co-administered with methadone.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z metadonom.
English: Skin and subcutaneous tissue disorders: General disorders and administration site conditions:
Slovenian: Splošne težave in spremembe na mestu aplikacije:
English: Virologic success HIV-1 RNA < 50 copies/mL
Slovenian: HIV-1 RNA < 50 kopij/ml Razlika zdravljenja
English: Nervous system disorders:
Slovenian: Bolezni živčevja: Pogosti:
English: No dose adjustment is required when Vitekta is co-administered with famotidine.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno s famotidinom.
English: Abacavir: AUC: ↔ Cmax: ↔
Slovenian: abakavir: AUC: ↔ Cmax: ↔
English: No clinically relevant pharmacokinetic differences due to ethnicity have been identified for boosted
Slovenian: Za ojačan elvitegravir ni bilo identificirane klinično pomembne farmakokinetične razlike glede na etnično pripadnost.
English: No dose adjustment is required when Vitekta is co-administered with etravirine.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z etravirinom.
English: No dose adjustment is required when Vitekta is co-administered with buprenorphine/naloxone.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z buprenorfinom/naloksonom.
English: No clinically relevant pharmacokinetic differences due to gender have been identified for boosted
Slovenian: Za ojačan elvitegravir ni bilo identificirane klinično pomembne farmakokinetične razlike glede na spol.
English: Elvitegravir (85 mg once daily) Atazanavir (300 mg once daily) Ritonavir (100 mg once daily)
Slovenian: telaprevir (750 mg trikrat dnevno)/ elvitegravir (85 mg enkrat dnevno) atazanavir (300 mg enkrat dnevno) ritonavir (100 mg enkrat dnevno)
English: Lopinavir/Ritonavir (400/100 mg twice daily)
Slovenian: dnevno) ritonavir (100 mg dvakrat dnevno)
English: Tenofovir disoproxil fumarate (300 mg once daily) Emtricitabine (200 mg once daily) Elvitegravir (50 mg once daily) Ritonavir (100 mg once daily)
Slovenian: Priporočilo glede sočasne uporabe z ritonavirjem ojačanega elvitegravirja tenofovir dizoproksilfumarat (300 mg enkrat dnevno) emtricitabine (200 mg enkrat dnevno) elvitegravir (50 mg enkrat dnevno) ritonavir (100 mg enkrat dnevno)
English: Interactions requiring dose adjustment of Vitekta
Slovenian: Kaj vsebuje zdravilo Vitekta
English: There are no data available to make dosing recommendations for co-administration with other doses of fosamprenavir (see section 4.2).
Slovenian: Podatkov za izdelavo priporočil o odmerjanju pri sočasnem dajanju z drugimi odmerki fosamprenavirja ni (glejte poglavje 4.2).
English: Please refer to the Summary of Product Characteristics for Vitekta 85 mg
Slovenian: Glejte povzetek glavnih značilnosti zdravila za zdravilo Vitekta 85 mg tablete.
English: When used in combination with darunavir, the dose of Vitekta should be 150 mg once daily.
Slovenian: Pri uporabi v kombinaciji z darunavirjem mora biti odmerek zdravila Vitekta 150 mg enkrat dnevno.
English: BOTTLE AND CARTON LABELLING
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI OZNAČEVANJE NA PLASTENKI IN ŠKATLI
English: See section 3, How to take
Slovenian: Glejte poglavje 3, Kako jemati zdravilo Vitekta.
English: A study of the pharmacokinetics of boosted elvitegravir was performed in non HIV-1 infected subjects with severe renal impairment (estimated creatinine clearance below 30 mL/min).
Slovenian: Pri osebah s hudo ledvično okvaro (očistek kreatinina manj kot 30 ml/min) brez okužbe z virusom HIV-1 so izvedli farmakokinetično študijo ojačanega elvitegravirja.
English: Cmax: ↓ 28%
Slovenian: Cmin: ↑ 43 %
English: HMG-CoA REDUCTASE INHIBITORS
Slovenian: Zaviralci proteaze HCV
English: No dose adjustment is required when Vitekta is co-administered with abacavir.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z abakavirjem.
English: No dose adjustment is required when Vitekta is co-administered with rosuvastatin.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z rosuvastatinom.
English: • nevirapine
Slovenian: • vetrovi (flatulenca)
English: No dose adjustment is required when Vitekta is co-administered with maraviroc.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z maravirokom.
English: Elvitegravir-resistant viruses show cross-resistance to the integrase strand transfer inhibitor raltegravir
Slovenian: Virusi, rezistentni na elvitegravir, kažejo v večini primerov navzkrižno rezistenco na zaviralca prenosa zapisa integraze, raltegravir (glejte poglavje 5.1).
English: Titanium dioxide (E171) Iron oxide yellow (E172)
Slovenian: Filmska obloga indigotin (E132) makrogol 3350 (E1521) polivinilalkohol (delno hidroliziran) (E1203) smukec (E553B) titanov dioksid (E171) rumeni železov oksid (E172)
English: Rosuvastatin (10 mg single dose) Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)
Slovenian: ZAVIRALCI REDUKTAZE HMG-CoA: rosuvastatin (10 mg enkratni odmerek) elvitegravir (150 mg enkrat dnevno) kobicistat (150 mg enkrat dnevno)
English: No dose adjustment is required when Vitekta is co-administered with zidovudine.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z zidovudinom.
English: Please refer to the Summary of Product Characteristics for Vitekta
Slovenian: Glejte povzetek glavnih značilnosti zdravila za zdravilo
English: Effects on drug levels
Slovenian: Mehanizem delovanja in farmakodinamični učinki
English: No dose adjustment is required when Vitekta is co-administered with omeprazole.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno z omeprazolom.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 85 mg of elvitegravir.
Slovenian: NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena filmsko obložena tableta vsebuje 85 mg elvitegravirja
English: Italia
Slovenian: España
English: Antifungals
Slovenian: Spol
English: Virologic success at week 48
Slovenian: Virološki uspeh v 48. tednu darunavir/ritonavir
English: CCR5 antagonists Maraviroc (150 mg twice daily) Elvitegravir (150 mg once daily) Ritonavir (100 mg once daily)
Slovenian: Zdravila za zdravljenje okužb z mikobakterijami rifabutin (150 mg na vsaka dva dni) elvitegravir (300 mg enkrat dnevno) ritonavir (100 mg enkrat dnevno)
English: Famotidine (40 mg once daily) Elvitegravir (150 mg once daily) Cobicistat (150 mg once daily)
Slovenian: ANTAGONISTI RECEPTORJEV H2 famotidin (40 mg enkrat dnevno) elvitegravir (150 mg enkrat dnevno) kobicistat (150 mg enkrat dnevno)
English: The in vivo relevance of these interactions is not clear.
Slovenian: Pomen interakcij
English: No dose adjustment is required when Vitekta is co-administered with stavudine.
Slovenian: Prilagoditev odmerka ni potrebna, če se zdravilo Vitekta uporablja sočasno s stavudinom.
English: Diergeneesk d., deet Iûs,
Slovenian: Diergeneesk d., deet Iûs, afl.
English: Protect from frost.
Slovenian: Zaščitite pred zamrzovanjem.
English: For that purpose wear gloves and a dust mask.
Slovenian: Zaradi tega morate nositi rokavice in protiprašno masko.
English: No health abnormalities were detected.
Slovenian: Odkrili niso nobenih zdravstvenih nepravilnosti.
English: Once opened, use by:
Slovenian: Po odprtju uporabite do:
English: If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Slovenian: Če opazite kakršne koli resne učinke ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite svojega veterinarja.